IL163884A0 - Treatment of central nervous systemdamage - Google Patents

Treatment of central nervous systemdamage

Info

Publication number
IL163884A0
IL163884A0 IL16388403A IL16388403A IL163884A0 IL 163884 A0 IL163884 A0 IL 163884A0 IL 16388403 A IL16388403 A IL 16388403A IL 16388403 A IL16388403 A IL 16388403A IL 163884 A0 IL163884 A0 IL 163884A0
Authority
IL
Israel
Prior art keywords
systemdamage
treatment
central nervous
cns
mammal
Prior art date
Application number
IL16388403A
Other languages
English (en)
Original Assignee
King S College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by King S College London filed Critical King S College London
Publication of IL163884A0 publication Critical patent/IL163884A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Purification Treatments By Anaerobic Or Anaerobic And Aerobic Bacteria Or Animals (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Carbon And Carbon Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IL16388403A 2002-03-04 2003-03-04 Treatment of central nervous systemdamage IL163884A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0205022.7A GB0205022D0 (en) 2002-03-04 2002-03-04 Materials and methods for the treatment of cns damage
PCT/GB2003/000901 WO2003074080A1 (en) 2002-03-04 2003-03-04 Treatment of central nervous system damage

Publications (1)

Publication Number Publication Date
IL163884A0 true IL163884A0 (en) 2005-12-18

Family

ID=9932221

Family Applications (3)

Application Number Title Priority Date Filing Date
IL16388403A IL163884A0 (en) 2002-03-04 2003-03-04 Treatment of central nervous systemdamage
IL163884A IL163884A (en) 2002-03-04 2004-09-02 Preparation of medicaments to promote neuronal plasticity
IL223875A IL223875A (en) 2002-03-04 2012-12-25 Use of chondroitinase in the preparation of a drug for use in a method of promoting neural flexibility

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL163884A IL163884A (en) 2002-03-04 2004-09-02 Preparation of medicaments to promote neuronal plasticity
IL223875A IL223875A (en) 2002-03-04 2012-12-25 Use of chondroitinase in the preparation of a drug for use in a method of promoting neural flexibility

Country Status (16)

Country Link
US (1) US20050118157A1 (ja)
EP (2) EP2277531A1 (ja)
JP (2) JP5112607B2 (ja)
AT (1) ATE490786T1 (ja)
AU (2) AU2003208466B2 (ja)
CA (1) CA2478645C (ja)
DE (1) DE60335244D1 (ja)
DK (1) DK1480674T3 (ja)
ES (1) ES2357227T3 (ja)
GB (1) GB0205022D0 (ja)
HK (1) HK1073430A1 (ja)
IL (3) IL163884A0 (ja)
MX (1) MXPA04008598A (ja)
PT (1) PT1480674E (ja)
SI (1) SI1480674T1 (ja)
WO (1) WO2003074080A1 (ja)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5340801A (en) * 2000-04-13 2001-10-30 Thomas N Wight Therapeutic compounds and methods
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) * 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
EP2301564A1 (en) * 2002-05-04 2011-03-30 Acorda Therapeutics, Inc. Compositions and methods for promoting neuronal outgrowth
WO2003102160A2 (en) 2002-06-03 2003-12-11 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from chondroitinase b
ES2366333T3 (es) * 2002-08-15 2011-10-19 Acorda Therapeutics, Inc. Proteína quimérica.
JP4571776B2 (ja) * 2002-11-05 2010-10-27 Ｊｘ日鉱日石エネルギー株式会社 潤滑油組成物
EP1897552B1 (en) 2003-04-18 2009-06-17 Biogen Idec MA Inc. Polymer-conjugated glycosylated neublastin
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
EP2353606B1 (en) * 2003-05-16 2013-04-17 Acorda Therapeutics, Inc. Compositions and methods for the treatment of CNS injuries
MX348062B (es) 2003-05-16 2017-05-26 Acorda Therapeutics Inc Mutantes que degradan proteoglicanos para tratamiento del snc.
AU2004247025B8 (en) * 2003-05-16 2011-06-30 Acorda Therapeutics, Inc. Fusion proteins for the treatment of CNS
CA2558984A1 (en) * 2004-03-10 2005-09-22 Massachusetts Institute Of Technology Recombinant chondroitinase abc i and uses thereof
ES2411504T3 (es) * 2004-05-18 2013-07-05 Acorda Therapeutics, Inc. Métodos de purificación de condroitinasa y formulaciones estables de la misma
WO2006023782A2 (en) 2004-08-19 2006-03-02 Biogen Ideca Ma Inc. Refolding transforming growth factor beta family proteins
CN102924585A (zh) * 2004-08-19 2013-02-13 比奥根艾迪克Ma公司 神经胚素变体
EP1904844A2 (en) * 2005-05-25 2008-04-02 The Johns-Hopkins University Compositions and methods for enhancing axon regeneration
US7485295B2 (en) 2005-09-26 2009-02-03 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase ABCI mutants
TWI501774B (zh) * 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
EP1993590B1 (en) * 2006-03-01 2013-12-25 Biogen Idec MA Inc. Compostions and methods for administering gdnf ligand family proteins
WO2008029493A1 (fr) * 2006-09-08 2008-03-13 Stelic Institute Of Regenerative Medicine, Stelic Institute & Co. Inhibiteur de dégénération de fibres nerveuses
CA2666536C (en) 2006-10-10 2018-08-07 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase abci mutants
ES2476253T3 (es) 2007-05-01 2014-07-14 Biogen Idec Ma Inc. P�ptidos de neublastina para su uso en el aumento de la vascularizaci�n en tejido con flujo sanguíneo deteriorado
WO2008149428A1 (ja) * 2007-06-05 2008-12-11 Glycoscience Laboratories, Inc. 自己免疫疾患、炎症及び神経疾患の治療剤及び予防剤
EP2205634A2 (en) * 2007-08-08 2010-07-14 Biogen Idec MA, Inc. Anti-neublastin antibodies and uses thereof
EP2217249A4 (en) * 2007-11-06 2011-10-12 Benaroya Res Inst INHIBITION OF VERSICANE BY ARNS AND OTHER MOLECULES
GB0723825D0 (en) * 2007-12-05 2008-01-23 Ucl Business Plc Composition
EP2286828B1 (en) * 2008-04-14 2016-05-18 National University Corporation Nagoya University Improving agent for neuropathic pain
EP2153844A1 (en) * 2008-08-14 2010-02-17 HAUBECK, Hans-Dieter Human hyaluronidases for axonal regrowth
WO2010100247A1 (en) 2009-03-06 2010-09-10 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Novel therapy for anxiety
US20110124706A1 (en) * 2009-11-25 2011-05-26 Zhigang He SOCS3 Inhibition Promotes CNS Neuron Regeneration
JP5885136B2 (ja) * 2011-01-31 2016-03-15 学校法人 愛知医科大学 高硫酸化コンドロイチン硫酸類の合成方法、高硫酸化コンドロイチン硫酸類、および解析用試薬
WO2012136768A1 (en) 2011-04-08 2012-10-11 Hans-Dieter Haubeck Use of mutants of human hyaluronidase ph-20 with increased chondroitinase activity for axonal regrowth
EP2773382A4 (en) 2011-11-01 2016-03-23 Childrens Medical Center CO-ACTIVATION OF MTOR AND STAT3 PATHWAYS TO PROMOTE NEURONAL SURVIVAL AND REGENERATION
US20150274815A1 (en) * 2012-09-25 2015-10-01 The United States of America, as represented by the Secretary, Department of Health & Human Servic Treatment of central nervous system (cns) injury
WO2014065669A1 (en) * 2012-10-26 2014-05-01 Stichting Vu-Vumc Methods of treatment and diagnosis for cognitive decline and memory impairment
CN105579578A (zh) * 2013-08-12 2016-05-11 贝纳罗亚研究院·弗吉尼亚梅森 用于免疫调节的4-甲基伞形酮治疗
WO2018029685A1 (en) * 2016-08-11 2018-02-15 Technion Research & Development Foundation Limited Compositions and methods for treating a fear memory

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
AU6872691A (en) * 1989-10-27 1991-05-31 Case Western Reserve University Inhibition of cell growth by keratan sulfate, chondroitin sulfate, dermatan sulfate and other glycans
JPH06502840A (ja) * 1989-10-27 1994-03-31 ケース ウェスタン リザーブ ユニバーシティ ケラタン硫酸、コンドロイチン硫酸、デルマタン硫酸及び他のグリカンによる細胞成長の阻害
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5496718A (en) 1992-06-26 1996-03-05 Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) Chondroitinase ABC isolated from proteus vulgaris ATCC 6896
US5773277A (en) 1992-06-26 1998-06-30 Seikagaku Kogyo Kabushiki Kaisha Crystalline chondroitinase isolated from Proteus vulgaris ATCC 6896
US5498536A (en) 1994-04-22 1996-03-12 American Cyanamid Company Chondroitinase II from Proteus vulgaris
WO1995029256A1 (en) 1994-04-22 1995-11-02 American Cyanamid Company Chondroitinases i and ii, methods of preparation, and use thereof
US6093563A (en) 1994-07-08 2000-07-25 Ibex Technologies R And D, Inc. Chondroitin lyase enzymes
US5997863A (en) 1994-07-08 1999-12-07 Ibex Technologies R And D, Inc. Attenuation of wound healing processes
JPH09194502A (ja) * 1995-11-13 1997-07-29 Seikagaku Kogyo Co Ltd 新規コンドロイチン硫酸プロテオグリカン、そのコア蛋白質、それをコードするｄｎａおよびそれに対する抗体
EP0875253B1 (en) * 1997-05-02 2005-04-06 Seikagaku Corporation Chondroitinase compositions
CA2346375C (en) * 1998-10-06 2013-04-23 Rush-Presbyterian-St. Luke's Medical Center Method for the treatment of chemonucleolysis
KR20040021697A (ko) * 2001-08-13 2004-03-10 유니버시티 오브 플로리다 리서치 파운데이션, 인크. 신경 조직 복구를 증진시키는 물질 및 방법
AU2003300012A1 (en) * 2002-12-30 2004-07-29 Indiana University Research & Technology Corporation Method of treatment for central nervous system injury

Also Published As

Publication number Publication date
JP2005526740A (ja) 2005-09-08
IL163884A (en) 2013-01-31
CA2478645C (en) 2011-11-29
SI1480674T1 (sl) 2011-04-29
AU2009200025A1 (en) 2009-02-05
EP2277531A1 (en) 2011-01-26
AU2003208466A1 (en) 2003-09-16
IL223875A (en) 2017-02-28
EP1480674B1 (en) 2010-12-08
DK1480674T3 (da) 2011-03-28
EP1480674A1 (en) 2004-12-01
CA2478645A1 (en) 2003-09-12
HK1073430A1 (en) 2005-10-07
US20050118157A1 (en) 2005-06-02
AU2003208466B2 (en) 2008-10-02
DE60335244D1 (de) 2011-01-20
PT1480674E (pt) 2011-03-15
JP5112607B2 (ja) 2013-01-09
ES2357227T3 (es) 2011-04-20
JP2010132682A (ja) 2010-06-17
MXPA04008598A (es) 2005-09-08
AU2009200025B2 (en) 2010-11-18
ATE490786T1 (de) 2010-12-15
WO2003074080A1 (en) 2003-09-12
GB0205022D0 (en) 2002-04-17

Similar Documents

Publication Publication Date Title
IL163884A0 (en) Treatment of central nervous systemdamage
IL267381A (en) A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
IL188249A0 (en) Cephalosporin related compounds for use in therapy
DK1373215T3 (da) Gelanamycinderivater egnet til behandling af cancer
ZA200204416B (en) Carbon dioxide enhancement of inhalation therapy.
NO20035025D0 (no) Anvendelse av osteopontin for behandling og/eller for å hindre nevrologiskesykdommer
WO2005004814A3 (en) Sirt1 and genetic disorders
EP0958824A3 (en) Olanzapine (zyprexa) in combination with fluoxetine (prozac), lithium or anticonvulsant for therapy of refractory depression
HUP0303900A2 (hu) Az arteminnek, a GDNF ligandum család egy tagjának új alkalmazása
ATE237680T1 (de) Transplantation von hämatopoietischen zellen
MXPA05012305A (es) Composiciones y metodos para el tratamiento de lesiones del snc.
MXPA05009986A (es) Tratamiento de la enfermedad de alzheimer.
WO2005013911A3 (en) Protective and therapeutic uses for tocotrienols
AU2003304173A1 (en) Compositions and methods for promoting neuronal outgrowth
AUPS255402A0 (en) Agents and methods for the treatment of disorders associated with oxidative stress
ITVR20020071A1 (it) Procedimento ed attrezzatura per l'appassimento dell'uva.
AU2003287513A8 (en) Inhibitors of beta-secretase, and their use for the prevention or treatment of alzheimer's disease or mild cognitive impairment
EP1210103A4 (en) INDUCED REGENERATION AND REPAIR OF DAMAGED NEURONES AND THE AXONMYELIN OF NERVES
SI1534286T1 (sl) Postopki za zdravljenje ali prepreŽŤevanje avtoimunskih bolezni z 2,4-pirimidindiaminskimi spojinami
WO2005013895A3 (en) Compositions and methods for the treatment of schizophrenia and addictive disorders
MX349462B (es) Composiciones y metodos para el tratamiento de lesiones del snc.
UA32146A (uk) Спосіб оцінки ефективності лікування пародонтита
UA32235A (uk) Спосіб моделювання закритої травми нирки в експерименті